1
59 pa&ents were studied 10 (16.9%) males Mean age at the &me of the study 50.4 ± 14.5 years Mean age at bronchiectasis diagnosis of 38.9 ± 17.1 years Natacha Santos 1 , Ana Leblanc 1 , Teresa Vieira 1 , Adelina Amorim 2 , José TorresCosta 1 1 Serviço de Imunoalergologia, Centro Hospitalar São João, E.P.E., Porto, Portugal 2 Serviço de Pneumologia, Centro Hospitalar São João, E.P.E., Porto, Portugal Primary immunodeficiency diseases (PID) are usually diagnosed during childhood, but might only be suspected in adulthood because of complica&ons as bronchiectasis. Aim: To assess the frequency of primary immunodeficiency diseases among adult pa&ents with noncys&c fibrosis bronchiectasis. Pa&ents with computerized tomography confirmed noncys&c fibrosis bronchiectasis followed in a specialized pulmonology prac&ce were inves&gated with: Serum immunoglobulins (Ig) and IgG subclasses Specific an&body responses to tetanus toxoid (total IgG and IgG1) and pneumococcal capsular polysaccharide (total IgG and IgG2 an&PCP) Subsequently, the opinion of an immunoallergologist was sought if further specific immunological inves&ga&ons were required. Primary immunodeficiencies are frequently diagnosed in adult pa&ents with noncys&c fibrosis bronchiectasis Although mild immunological defects were the most frequent, other more severe immunodeficiency diseases needing specific treatment were also present Pa&ents with borderline an&PCP specific an&bodies need further tes&ng as low normal results do not predict response to vaccina&on. Possibly serotypespecific an&bodies could be a useful addi&onal tool in evalua&ng these pa&ents. Two with a previously diagnosed immunodeficiency 1 aged 34 years and AID deficiency (hiperIgM syndrome), under IV immunoglobulin G replacement 1 aged 29 years with decreased IgA and IgG2, elevated IgM, absence of specific an&bodies response and decreased memory B cells, under evalua&on Four with newly diagnosed immunodeficiency 3 pa&ents with IgA deficiency (≤0.06g/L) 1 aged 73 years with decreased IgM (0.21g/L), progressive decrease in IgG (5.37g/L) and absence of response to pneumococcal vaccina&on* (immunosenescence?) An immunodeficiency was present in 6 (10.2%) pa<ents : An addi<onal number of 5 (8.5%) pa<ents had “borderline levelsof an<PCP specific an<bodies . These pa&ents had unknow pneumococcal vaccina&on/infec&on status and are under further inves&ga&on. IgG 2 an&PCP IgG an&PCP Mean=13.4 SD=7.65 Mean=5.0 SD=3.01 1.54§ 5.57‡ 0.54§ 1.75‡ Table 1. Pa&ents with IgG 2 an&PCP below 1.75 (p15) and normal IgG an&PCP levels were arbitrarily considered as “borderline”. n.p.: not performed. Age at IgG an&PCP evalua&on Age(years) Before Aker An&pneumococcal vaccina&on IgG an&PCP IgG2 an&PCP IgG an&PCP IgG2 an&PCP 51 2.25 0.53 n.p. n.p. 47 5.58 1.28 n.p. n.p. 27 1.65 0.52 n.p. n.p. 60 11.6 0.23 n.p. n.p. 41 2.01 1.53 n.p. n.p. 70* 2.08 0.94 2.57 0.98 62 2.61 0.62 13.5 3.92 44 2.22 0.57 17.4 4.43 Figure 1. Histogram for IgG and IgG 2 an&PCP levels (mg/dL) with threshold provided by the supplier (§) and percen&l 15 (p15) in our cohort (‡) Schauer U, Stemberg F, Rieger CH, Büpner W, Borte M, Schubert S, et al. Levels of an&bodies specific to tetanus toxoid, Haemophilus influenzae type b, and pneumococcal capsular polysaccharide in healthy children and adults. Clin Diagn Lab Immunol. 2003 Mar;10(2):2027. Li AM, Sonnappa S, Lex C, Wong E, Zacharasiewicz A, Bush A, Jaffe A. NonCF bronchiectasis: does knowing the ae&ology lead to changes in management? Eur Respir J. 2005 Jul;26(1):814. Orange JS, Ballow M, S&ehm ER, Ballas ZK, Chinen J, De La Morena M, et al. Use and interpreta&on of diagnos&c vaccina&on in primary immunodeficiency. J Allergy Clin Immunol. 2012 Sep;130(3 Suppl):S124. [email protected]

Adult diagnosed primary immunodeficiency diseases in patients with bronchiectasis

Embed Size (px)

Citation preview

Page 1: Adult diagnosed primary immunodeficiency diseases in patients with bronchiectasis

59  pa&ents  were  studied  

10  (16.9%)  males  

Mean  age  at  the  &me  of  the  study  50.4  ±    14.5  years  

Mean  age  at  bronchiectasis  diagnosis  of  38.9  ±  17.1  years  

Natacha  Santos1,  Ana  Leblanc1,  Teresa  Vieira1,  Adelina  Amorim2,  José  Torres-­‐Costa1      

1Serviço  de  Imunoalergologia,  Centro  Hospitalar  São  João,  E.P.E.,  Porto,  Portugal  2Serviço  de  Pneumologia,  Centro  Hospitalar  São  João,  E.P.E.,  Porto,  Portugal  

Primary   immunodeficiency   diseases   (PID)  

are   usually   diagnosed   during   childhood,  

but  might   only   be   suspected   in   adulthood  

because  of  complica&ons  as  bronchiectasis.    

Aim:   To   assess   the   frequency   of   primary  

immunodeficiency   diseases   among   adult  

pa&en t s   w i th   non -­‐ cy s&c   fib ros i s  

bronchiectasis.  

Pa&ents   with   computerized   tomography   confirmed   non-­‐cys&c   fibrosis  

bronchiectasis   followed   in   a   specialized   pulmonology   prac&ce   were   inves&gated  

with:  

-­‐  Serum  immunoglobulins  (Ig)  and  IgG  subclasses  

-­‐  Specific   an&body   responses   to   tetanus   toxoid   (total   IgG   and   IgG1)   and  

pneumococcal  capsular  polysaccharide  (total  IgG  and  IgG2  an&-­‐PCP)  

Subsequently,  the  opinion  of  an  immunoallergologist  was  sought  if  further  specific  

immunological  inves&ga&ons  were  required.  

ü  Primary  immunodeficiencies  are  frequently  diagnosed  in  adult  pa&ents  with  non-­‐cys&c  fibrosis  bronchiectasis  

ü  Although  mild  immunological  defects  were  the  most  frequent,  other  more  severe  immunodeficiency  diseases  needing  

specific  treatment  were  also  present  

ü  Pa&ents  with  borderline  an&-­‐PCP  specific  an&bodies  need  further  tes&ng  as  low  normal  results  do  not  predict  response  

to  vaccina&on.  Possibly  serotype-­‐specific  an&bodies  could  be  a  useful  addi&onal  tool  in  evalua&ng  these  pa&ents.  

Two  with  a  previously  diagnosed  immunodeficiency  

•  1  ♀   aged   34   years   and   AID   deficiency   (hiper-­‐IgM   syndrome),  

under  IV  immunoglobulin  G  replacement  

•  1  ♂   aged   29   years  with   decreased   IgA   and   IgG2,   elevated   IgM,  

absence  of  specific  an&bodies  response  and  decreased  memory  B  

cells,  under  evalua&on  

Four  with  newly  diagnosed  immunodeficiency  

•  3  pa&ents  with  IgA  deficiency  (≤0.06g/L)  

•  1  ♀   aged   73   years   with   decreased   IgM   (0.21g/L),     progressive  

decrease   in   IgG   (5.37g/L)   and   absence   of   response   to  

pneumococcal  vaccina&on*  (immunosenescence?)  

An  immunodeficiency  was  present  in  6  (10.2%)  pa<ents:  

An  addi<onal  number  of  5   (8.5%)  pa<ents  had  “borderline   levels”  

of   an<-­‐PCP   specific   an<bodies.   These   pa&ents   had   unknow  

pneumococcal   vaccina&on/infec&on   status   and   are   under   further  

inves&ga&on.  

 

IgG2  an&-­‐PCP  

IgG  an&-­‐PCP  Mean=13.4  SD=7.65  

Mean=5.0  SD=3.01  

1.54§   5.57‡  

0.54§   1.75‡  

Table   1.   Pa&ents  with   IgG2   an&-­‐PCP   below   1.75   (p15)   and   normal   IgG  an&-­‐PCP   levels   were   arbitrarily   considered   as   “borderline”.   n.p.:   not  performed.  ✧Age  at  IgG  an&-­‐PCP  evalua&on  

Age✧  (years)  

Before   Aker  An&-­‐pneumococcal  vaccina&on  

 IgG      an&-­‐PCP  

IgG2    an&-­‐PCP  

 IgG      an&-­‐PCP  

IgG2    an&-­‐PCP  

51   2.25   0.53   n.p.   n.p.  47   5.58   1.28   n.p.   n.p.  27   1.65   0.52   n.p.   n.p.  60   11.6   0.23   n.p.   n.p.  41   2.01   1.53   n.p.   n.p.  70*   2.08   0.94   2.57   0.98  62   2.61   0.62   13.5   3.92  44   2.22   0.57   17.4   4.43  

Figure   1.   Histogram   for   IgG   and   IgG2   an&-­‐PCP   levels  (mg/dL)  with  threshold  provided  by  the  supplier  (§)  and  percen&l  15  (p15)  in  our  cohort  (‡)    

Schauer  U,  Stemberg  F,  Rieger  CH,  Büpner  W,  Borte  M,  Schubert  S,  et  al.  Levels  of  an&bodies  specific  to  tetanus  toxoid,  Haemophilus  influenzae  type  b,  and  pneumococcal  capsular  polysaccharide  in  healthy  children  and  adults.  Clin  Diagn  Lab  Immunol.  2003  Mar;10(2):202-­‐7.  

Li  AM,  Sonnappa  S,  Lex  C,  Wong  E,  Zacharasiewicz  A,  Bush  A,  Jaffe  A.  Non-­‐CF  bronchiectasis:  does  knowing  the  ae&ology  lead  to  changes  in  management?  Eur  Respir  J.  2005  Jul;26(1):8-­‐14.  

Orange  JS,  Ballow  M,  S&ehm  ER,  Ballas  ZK,  Chinen  J,  De  La  Morena  M,  et  al.  Use  and  interpreta&on  of  diagnos&c  vaccina&on  in  primary  immunodeficiency.  J  Allergy  Clin  Immunol.  2012  Sep;130(3  Suppl):S1-­‐24.  

     

[email protected]